Climb Bio Nears Budoprutug Phase 2 Data Readout In Rare Kidney Disease; Stock In Focus

Climb Bio reported Phase 1 results for CLYM116, showing sustained APRIL suppression through 12 weeks and reductions in IgA and Gd-IgA1. A single dose of at least 480 mg suppressed free APRIL by 90% or more, supporting a potential every-12-week regimen. The antibody was generally well tolerated. Phase 2 trial is enrolling, with initial data expected in the first half of 2027, and a Phase 3 trial is expected to begin in 2027, pending regulatory feedback.

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116 at ASN Kidney Week 2026, showing 90% free APRIL suppression and 70% Gd-IgA1 reduction. The drug has a 33-day half-life, supports Q12W dosing, and is generally well-tolerated. NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in 2027, and a global Phase 3 trial is planned for 2027.

Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116, an IgA nephropathy drug, at Kidney Week 2026. Trials in Australia and China showed sustained APRIL suppression and tolerability. Phase 2 trial is enrolling, with data expected in 2027.

Climb Bio Inc. (CLYM) rose 10.9% after Deutsche Bank initiated coverage with a Buy rating and $28.00 target, citing its autoimmune drug pipeline. The bank noted recent valuation compression reflected sector-wide selloff, not company-specific issues. Multiple analysts maintain bullish ratings with targets up to $40, citing positive clinical data. Broader market gains and biotech sector stabilization also supported the move.

Climb Bio (CLYM) shares rose 10% after Deutsche Bank initiated coverage with a Buy rating and $28 price target, citing its autoimmune pipeline and attractive valuation. Analyst David Hoang highlighted CLYM116 as a key growth driver and noted upcoming clinical updates as catalysts. The firm sees significant commercial potential in the company's pipeline, including budoprutug for multiple B cell-mediated disorders.